Blockade of VEGFR-1 activity in tumor-bearing mice (subcutaneously injected with murine Lewis lung carcinoma or B16 melanoma cells) by intraperitoneal treatment with the anti-murine VEGFR-1 mAb MF-1, did not affect the number of BMDCs in the pre-metastatic lung. This evidence concerns the gene FLT1 and melanoma.